Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC16A1 antisense RNA 1 (SLC16A1-AS1)
- Target
- SLC16A1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Non-protein coding RNA, Gene regulatory RNA
01
Overview
SLC16A1 antisense RNA 1 (SLC16A1-AS1) is a long non-coding RNA transcribed antisense to the SLC16A1 gene (lactate transporter MCT1) and serves as a regulatory molecule involved in metabolic reprogramming of cancer cells. It forms complexes with transcription factors such as E2F1, facilitating upregulation of SLC16A1/MCT1 and genes like PPARA, thus promoting a metabolic phenotype favoring cancer cell invasiveness. SLC16A1-AS1 is regulated in a cancer-type-specific manner and acts by modulating microRNAs and gene stability, making it a promising biomarker and candidate therapeutic target in oncology. It does not encode a protein and is not a classical drug target (such as receptor or enzyme), but may be targeted by RNA therapeutics.
- Other names
- ENST00000421157.1HP08777hypothetical protein HP08777LINC01357long intergenic non-protein coding RNA 1357
02
Mechanism of action
Gene silencing with antisense oligonucleotides or CRISPR-Cas9 disrupts SLC16A1-AS1, reducing cancer cell invasiveness. It also involves potential microRNA modulation, such as sponging miR-143-3p (renal cancer) and miR-515-5p (colorectal cancer).
03
Biological functions
Transcriptional regulationMetabolic reprogramming (including regulation of glycolysis, oxidative phosphorylation, and fatty acid β-oxidation)Modulation of tumor invasivenessRegulation of neighboring gene SLC16A1/MCT1 expressionmicroRNA sponging (e.g., miR-143-3p, miR-515-5p)Cell invasion (in cancer context)Induction of macrophage polarization (e.g., M2)
04
Disease associations
Cancer (especially bladder cancer, colorectal cancer, renal cell carcinoma, hepatocellular carcinoma)Prognostic biomarker in cancer (CRC, RCC, HCC)Modulator of cancer progression (via metabolic reprogramming or microRNA interaction)
05
Safety considerations
Targeting lncRNAs may pose therapeutic challenges: difficulty in specific delivery, off-target effects, limited knowledge on systemic functionSLC16A1-AS1 is not involved in essential metabolic enzyme or receptor functions, reducing risk of direct systemic toxicity, but careful validation is needed
06
Interacting drugs
Antisense oligonucleotides targeting SLC16A1-AS1 knockdown (experimental)
1 more in the full profile.
07
Biomarkers
SLC16A1-AS1 expression as a prognostic biomarker in bladder cancer, colorectal cancer, renal cell carcinoma, and hepatocellular carcinoma (high levels generally associate with poor survival)SLC16A1-AS1/MCT1 co-expression as a negative prognostic marker in multiple cancer types
Beyond the preview
Go deeper on SLC16A1 antisense RNA 1 (SLC16A1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLC16A1 antisense RNA 1 (SLC16A1-AS1).